LONG-TERM MUSCLE IMPROVEMENTS SHOWN IN GENE THERAPY STUDY IN MICE
COLUMBUS, Ohio – Injecting a gene responsible for making a specific protein into a mouse that’s used as a model for muscular dystrophy can lead to long-term improvements in the animal’s muscle size and strength, a new study shows.
Researchers investigating the gene delivery of the protein in animals suggest the results warrant testing the same approach in human clinical trials for diseases associated with muscle wasting, including Duchenne muscular dystrophy, the most common form of the childhood disorder.
Scientists used a safe virus to deliver a protein called follistatin into the leg muscles of young and older mice that have a disorder similar to human Duchenne muscular dystrophy (DMD). The protein inhibits the activity of myostatin, identified in previous research as a protein that limits muscle growth. Both young and old mice treated with the therapy responded with increased muscle mass and improvements in strength.
The study also takes a rare long look at the effects of the therapy.
“Many studies don’t evaluate a therapy over a two-year time span. In our studies, the beneficial effects persisted over the two years we evaluated,” Kaspar said. “Furthermore, this long-term study shows that there were no obvious safety problems with either the gene therapy virus or the therapeutic protein, follistatin.”
The research is reported online in this week’s edition of Proceedings of the National Academy of Sciences.
In studies of younger mdx mice, the therapy was administered when they were 3 weeks old. At age 5 months, they had a larger body mass and higher muscle weight than did comparison animals.
Mice used for comparison were treated with an inactive fluorescent protein that allowed researchers to monitor which cells were affected by the experimental gene therapy technique.
Before testing follistatin in mdx mice, the scientists first tested the protein in normal mice and found after 725 days that they, too, had increased muscle mass and better grip strength when compared to untreated mice.
The resulting muscle enhancements in all of the treated mice were evident at the site of injection as well as in tricep muscles, meaning the therapy was able to affect other muscle cells in the body. To deliver the protein, scientists used an adeno-associated virus that had been manipulated to find its way into target cells without promoting any spread of the virus itself.
This research was supported by Project A.L.S., the Myositis Association, Roger Stevens and a National Research Service Award fellowship.






Reply With Quote











